Mesoblast WKN: A0DNPW ISIN: AU000000MSB8 Kürzel: LWB Branche: Gesundheit, Biotechnologie
|
|
Themen zum Wert | ||
|---|---|---|---|
| 1 | MESOBLAST Hauptdiskussion |
Kursdetails
| Geld (bid) | 0,498 (898) |
|---|---|
| Brief (ask/offer) | 0,520 (898) |
| Spread | 4,231 |
| Geh. Stück | 1.600 |
| Eröffnung | 0,505 |
| Vortag | 0,183 |
| Tageshoch | 0,515 |
| Tagestief | 0,490 |
| 52W Hoch | 0,895 |
| 52W Tief | 0,172 |
Tagesvolumen
| in EUR gehandelt | 21.600 Stk |
|---|---|
| in USD gehandelt | 1 Stk |
| in CHF gehandelt | 2.000 Stk |
| in AUD gehandelt | 0 Stk |
| Gesamt | 23.601 Stk |
Partner-News
AnzeigeGestern 18:00 Uhr • Partner • Societe Generale
Gestern 16:45 Uhr • Partner • Societe Generale
Gestern 15:46 Uhr • Partner • onemarkets Blog
Gestern 15:33 Uhr • Partner • Societe Generale
Gestern 15:00 Uhr • Partner • BNP Paribas
Aktien-News
6:19 Uhr • Artikel • dpa-AFX
6:18 Uhr • Artikel • dpa-AFX
6:18 Uhr • Artikel • dpa-AFX
6:17 Uhr • Artikel • dpa-AFX
Geld/Brief Kurse
Neu laden| Börse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
|---|---|---|---|---|---|---|---|
| L&S Exchange | 0,498 | 898 Stk | 0,520 | 898 Stk | 1713214811 15. Apr | 1.600 Stk | 0,509 EUR |
| Nasdaq OTC | 1712238555 4. Apr | 1 Stk | 0,465 USD | ||||
| Baader Bank | 0,494 | 5.888 Stk | 0,525 | 5.888 Stk | 1713210111 15. Apr | 0,510 EUR | |
| Frankfurt | 0,500 | 5.000 Stk | 0,510 | 1.961 Stk | 1713187742 15. Apr | 0,500 EUR | |
| Tradegate | 0,494 | 1.700 Stk | 0,525 | 1.600 Stk | 1713212781 15. Apr | 10.000 Stk | 0,510 EUR |
| Lang & Schwarz | 0,498 | 898 Stk | 0,520 | 898 Stk | 1713214802 15. Apr | 10.000 Stk | 0,509 EUR |
| TTMzero RT | 1713210111 15. Apr | 0,510 EUR | |||||
| Berlin | 0,464 | 11.700 Stk | 0,555 | 11.700 Stk | 1713210362 15. Apr | 0,505 EUR | |
| Hamburg | 0,500 | 5.000 Stk | 0,510 | 1.961 Stk | 1713188274 15. Apr | 0,490 EUR | |
| München | 0,494 | 1.700 Stk | 0,525 | 1.600 Stk | 1713160818 15. Apr | 0,490 EUR | |
| Stuttgart | 0,436 | 20.000 Stk | 0,500 | 20.000 Stk | 1713169884 15. Apr | 0,412 EUR | |
| BX Swiss | 0,482 | 21.117 Stk | 0,500 | 21.117 Stk | 1713196800 15. Apr | 2.000 Stk | 0,501 CHF |
| Sydney | 1713161462 15. Apr | 0,830 AUD | |||||
| Gettex | 0,494 | 5.888 Stk | 0,525 | 5.888 Stk | 1713210240 15. Apr | 0,510 EUR | ges. 23.601 Stk |
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 375,9 Mio. |
| Anzahl der Aktien |
| 737,1 Mio. |
Termine
| 30.05.2024 | Quartalsmitteilung |
|---|---|
| 29.07.2024 | Quartalsmitteilung |
| 02/25 | Quartalsmitteilung |
Grundlegende Daten zur MESOBLAST Aktie
| Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| KUV | 58,95 | 201,05 | 69,55 | 122,80 | - | - | - |
| Ergebnis je Aktie (bereinigt) | -0,13 | -0,15 | -0,12 | -0,10 | -0,60 | - | - |
| Cashflow | -56,4 Mio. | -0,1 Mrd. | -65,8 Mio. | -63,3 Mio. | - | - | - |
| Eigenkapitalquote | 74,88 % | 78,07 % | 75,07 % | 74,97 % | - | - | - |
| Verschuldungsgrad | 33,55 | 28,09 | 33,22 | 33,39 | - | - | - |
| EBIT | -79,1 Mio. | -0,1 Mrd. | -81,0 Mio. | -69,1 Mio. | - | - | - |
| Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| KCV | -29,47 | -12,57 | -7,73 | -15,35 | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | -22,67 | -13,40 | -5,80 | -12,28 | -1,11 | - | - |
| Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Umsatzerlöse | 32,2 Mio. | 7,5 Mio. | 10,2 Mio. | 7,5 Mio. | - | - | - |
| Ergebnis vor Steuern | -87,4 Mio. | -99,6 Mio. | -91,6 Mio. | -82,1 Mio. | - | - | - |
| Steuern | -9,4 Mio. | -0,8 Mio. | -0,2 Mio. | -0,2 Mio. | - | - | - |
Info MESOBLAST Aktie
Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.